This article is part of our ongoing series exploring key tax considerations across the biotech lifecycle—from funding through exit.
Collaboration agreements are fundamental to the biotech industry. Early-stage companies often partner with larger pharmaceutical organizations to access capital, develop clinical capabilities, and commercialize. These arrangements are essential to the industry, but their tax treatment is not always straightforward.
One important question is whether a collaboration agreement is treated as a sale of intellectual property or as a license (or something else). That distinction can affect if and when income is recognized to the purported licensor, how payments are characterized, and how the economics of the arrangement are ultimately taxed.
Why Characterization Matters
If an agreement is characterized as a sale, the transfer of intellectual property will typically trigger immediate gain recognition under section 1001, subject to partial deferral under the installment sale regime. If it is treated as a license, however, payments such as upfront fees or royalties are generally recognized as ongoing income to compensate the licensor for the use of the intellectual property rather than sale proceeds.
In practice, collaboration agreements often include features of both. That is what makes the analysis so important: the tax treatment does not necessarily depend on the label given to the agreement, but rather on the substance of the rights being transferred.
What Shapes the Tax Outcome
A key consideration is whether “all substantial rights” to the underlying intellectual property have been transferred. Agreements that preserve meaningful rights for the original owner—such as limits based on geography, duration, or field of use—are more likely (but not necessarily) treated as licenses. Broader transfers, by contrast, tend to support sale treatment, especially when there is no residual interest associated with the license of intellectual property.
The surrounding contractual terms also matter. Provisions that preserve the licensor’s ability to further exploit the intellectual property, define a limited field of use, or establish a fixed term can all point toward license treatment. Payment structure is also another indicator. Ongoing royalties often align more naturally with licensing, while lump-sum consideration may support sale treatment, depending on the broader facts and structure of the arrangement.
Where Structuring Decisions Carry Risk
The consequences of classification can be significant. Misclassification may lead to unexpected tax liabilities, timing and character mismatches, acceleration of income into periods where income mitigating tax attributes to not exist or are otherwise unavailable, reporting challenges, or a tax result that does not align with the intended economics of the deal. In some cases, it can also affect valuation and the way the transaction is modeled internally.
The analysis also does not end with the sale-versus-license question alone. Collaboration agreements often intersect with other tax considerations, including joint venture structuring and cost-sharing arrangements, which themselves can result in potential “disguised sale” treatment when the contributor of the intellectual property also receives distributions proceeds and there is a direct link between the two. As a result, tax treatment should be evaluated as part of the broader transaction structure, not as a secondary review after core business terms are set.
Looking Beyond the Initial Analysis
For biotech companies, collaboration is not optional—it is often central to advancing science or bringing products to market. But because these agreements sit at the intersection of intellectual property, financing, and commercialization strategy, the tax implications should be evaluated with the same level of rigor as the commercial terms.
How We Help
WilliamsMarston supports biotech companies in structuring and evaluating collaboration agreements and helping ensure they align with the business objectives and intended economic outcomes. If you are entering into or renegotiating a collaboration agreement, we would be happy to review the structure and identify key tax considerations before execution.
